newsThe COVID-19 vaccine candidate BNT162b2, made by Pfizer and BioNTech,…
9 November 2020 | By Victoria Rees (European Pharmaceutical Review)
The COVID-19 vaccine candidate BNT162b2, made by Pfizer and BioNTech, has demonstrated over 90 percent efficacy in its first interim analysis during its Phase III trial.